Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 1.45% 70.00 69.00 71.00 71.00 69.00 69.00 470,290 16:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.9 5.5 0.8 86.4 318

Ekf Diagnostics Share Discussion Threads

Showing 3151 to 3175 of 3175 messages
Chat Pages: 127  126  125  124  123  122  121  120  119  118  117  116  Older
DateSubjectAuthorDiscuss
07/3/2021
22:09
Brilliant. Am sure every one on this board is well versed into the technicalities of the article you have copied and pasted.
tongosti
07/3/2021
17:29
I have been catching up in a few areas that I have neglected. In 2018 EKF Diagnostics signed an exclusive agreement with Oragenics, Inc. (NYSE American: OGEN), a Florida-based biopharmaceutical company, for the manufacturing of Oragenics’ lantibiotic bulk drug substances in the United States. I note the following Presentation and recent news flow - • Lantibiotics are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacterial strains to attack competing bacterial strains • Platform: >700 lantibiotic structures created, potentially generating a pipeline of new compounds • Platform provides potential for development in multidrug resistant infections: − Methicillin Resistant Staphlococcus aureus (MRSA) − Vancomycin Resistant Enterococci (VRE) − Virulent Clostridium difficile − Gram(-) infections Novel class of peptide antibacterial compounds called Lantibiotics • Activity against a variety of MDR infections, believed to be the next human health crisis • Lead lantibiotic OG716 addresses C. difficile – a significant infection identified by the CDC. They estimate filing for FDA IND (Investigational New Drug (IND) Application) in Q2 2021, but this was subject to having adequate available capital to complete requisite studies. Presentation November 2020, Lantibiotics page 18 onwards - hTTps://d1io3yog0oux5.cloudfront.net/_3163672321476757073a795d523eea69/oragenics/db/224/647/pdf/14558382v1+-+Oragenics+Investor+Deck+11+14+20+AGP+FINAL.pdf February 12, 2021 TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Officer of Oragenics, said, “We are delighted that we were able to raise capital to fund our operations through a number of anticipated key value-creating milestones towards the initiation of the Phase 2 clinical trial of our SARS CoV-2 vaccine, Terra CoV-2. In addition, we will be able to advance our lantibiotics program, which is directed at solving the problem of multidrug-resistant organisms. hTTps://www.oragenics.com/news-media/press-releases/detail/123/oragenics-announces-recent-capital-raise-and-warrant Oragenics are thus funded to advance and file for FDA IND, and I assume they will require further product to support that. And if that filing is ultimately successful, one can imagine that very large bulk volumes will be required to address such an important issue as antibiotic-resistant infections (this might also be of particular interest to ESG Investment Funds?)
wan
07/3/2021
16:55
Mirandaj....You may be interested in the interview earlier today with Susan Hopkins from Public Health England on the Andrew Marr show (if you had not seen it), regarding lateral flow tests, confirmatory pcr tests, sequencing/variants and being very prepared for a difficult autumn/winter (Covid and Flu, even if it does not arrive) - For the Susan Hopkins interview scroll to just over 30 mins in - hTTps://www.bbc.co.uk/iplayer/episode/m000t17r/the-andrew-marr-show-07032021
wan
07/3/2021
09:12
Lateral Flow tests do tend to have a reputation as giving too many false positives and negatives and this may well increase with the children self testing... https://bidstats.uk/tenders/2021/W09/746193438 Tenders for £8 billion Lateral Flow.
mirandaj
07/3/2021
09:07
Schools are back tomorrow so perhaps he will be too busy taunting others in the playground during the day instead.
darryn1
06/3/2021
15:59
Sometime ago after the Tongue tried to directly message me decided to firstly not read it and secondly to block his/her messages in the forum. The result has been a tidier screen populated with comments and observations from people with some insight into what is happening to the company and its environment rather than peddling idle comments from the sidelines based on hunches a few shareholders may be selling or buying, and trying to look for something more sinister than they are are buying something else whether shares or completely different and not playing hers/his hunches about market directions.
welshborderer
05/3/2021
22:17
Whatever you say Carlo.
tongosti
05/3/2021
15:19
Sense of humour very intact. Loving life. And it gives me a glow to know I have had nothing to do with siring the likes of you.....
charliec51
05/3/2021
15:19
Sense of humour very intact. Loving life. And it gives me a glow to know I have had nothing to do with siring the likes of you.....
charliec51
04/3/2021
18:45
Sense of humour failing you dad?
tongosti
04/3/2021
17:41
For the sake of humanity and evolution do grow up.
charliec51
04/3/2021
08:59
Morning old chap.
tongosti
04/3/2021
07:45
PrimeStore┬« Molecular Transport Medium (MTM) was invented in 2006 in preparation for a worldwide pandemic, which at the time was expected to be H5N1 influenza. It was designed to rapidly inactivate viruses, bacteria and pathogens within the sample and stabilize the RNA and DNA to provide safer and more efficient workflow for molecular testing and sequencing. I note that the Executive Vice President Global Business Development at Longhorn Vaccines highlighted the following recent ThermoFisher article - Rapid Genetic Sequencing for COVID-19 Global Surveillance By Behind The Bench Staff 03.01.2021 With more strains of SARS-CoV-2 appearing in communities across the globe, there is a growing call for national and international collaboration to understand these variants, including whether any are more infectious and how they are spreading. While PCR is a very important and scalable tool that is being used extensively in labs across the globe for diagnosis of COVID, it cannot provide deep insight into the virus’s full genome – this is where the advanced technology of next-generation sequencing (NGS) comes into play. Last March, Thermo Fisher Scientific introduced the Ion AmpliSeq SARS-CoV-2 Research Panel to aid in COVID-19 epidemiological research and contact tracing efforts using rapid NGS. Labs around the world have been using the panel to study how the virus is transmitted and decipher changes in its genetic code. Now, recognizing the pressing need to ramp up efforts to identify and track the newly identified strains, as well as emerging variants, additional clinical laboratory directors are joining global efforts to identify variants among patients who test positive for COVID-19. Q: Why is there a growing urgency to ramp up SARS-CoV-2 sequencing efforts? This urgency has come partly from realizing that here in the United States, we had only sequenced a fraction of the genomes necessary to identify and track strains. The combination of regulatory initiatives and proposed legislation to fund surveillance with up to $2BN has drawn growing awareness and demand for wider-spread sequencing. Full article - hTTps://www.thermofisher.com/blog/behindthebench/rapid-genetic-sequencing-for-covid-19-global-surveillance/
wan
03/3/2021
21:27
I always say that am completely agnostic re direction of my next trade. If there is indeed further upside as you say then sure as day I will jump back in as soon as Mr Market breaks out North. Until then - not really a fan of giving the tape the benefit of the doubt.
tongosti
03/3/2021
19:30
never a truer word written
srichardson8
03/3/2021
18:43
No need - imo there's still lots of upside here. Run your winners.....that's how I've done so well since I started this lark.
rivaldo
03/3/2021
18:14
HahahaDid you cash in before the share price came to a grinding halt? Lol.
tongosti
03/3/2021
15:35
Cheers pal :o)) Actually it worked last time too - just look at the rising chart from early September to November last year and you'll get the idea.....
rivaldo
03/3/2021
13:48
You were also expecting the exact same following the last one, if memory serves? Hopefully second time lucky pal.
tongosti
03/3/2021
11:47
I'd expect a nice run-up in the share price prior to the results on 30th March - and hopefully afterwards! Particularly given the year end trading statement: Https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/trading-update/202101120700063139L/ " Full year performance expected to be comfortably ahead of upgraded market consensus Q1 2021 performance to materially exceed management expectations EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations..... ....With continued strong performance in the core business and a number of indicative orders for PrimeStore MTM for the first quarter 2021 that are likely to be realised, the Board is confident that performance for the first quarter of 2021 will be materially ahead of current management expectations, and the first quarter of 2020."
rivaldo
03/3/2021
10:03
Good timekeeping today pal - 7:36. Well done.
tongosti
03/3/2021
07:36
An interesting comparison - Last years Notice of FY Results announcement contained the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/81906145 Todays announcement contains the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products. In 2020, EKF developed a range of COVID-19 testing products including PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under licence, and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise measurement of COVID-19 IgG antibodies. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/84481970 In my opinion only, this further supports my view that PrimeStore products will become core EKF products i.e. in constant use for the foreseeable (as perhaps exemplified by SBI's expansion in the US), and in that I also include country surveillance and preparedness.
wan
03/3/2021
07:21
And....EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its preliminary results for the year ended 31 December 2020 on Tuesday 30 March 2021.
wan
03/3/2021
07:18
I note Source Bio's news today - 03 March 2021 RNS REACH SourceBio International plc ("SourceBio", the "Company" or the "Group") US expansion of COVID-19 testing services COVID-19 testing services to be offered from San Diego facilities SourceBio International plc (AIM: SBI), the international provider of integrated state-of-the-art laboratory services and products , announces that its laboratory operations in San Diego, California, are to be expanded to include COVID-19 qPCR testing services. The division based in the Torrey Pines Genomics hub of the US, and home to prestigious as the Scripps Research Center, will mirror that of the Company's set up in Nottingham, England, and is expected to be fully operational in Q2 2021. The Group's existing San Diego facility currently houses Stability Storage Solutions and Genomics business units and the enhanced space is planned to have the capacity to process up to circa 5,000 samples per day with opportunities for continued growth. SourceBio already has cGMP, HPRA and FDA accredited facilitates in the UK, Ireland and United States for a global client base. The increased laboratory capacity of 1642 square feet will adhere to requirements and be fully compliant with guidelines from the FDA. The Company expects to receive the necessary accreditation to begin processing samples within the planned timeframe. The site will also benefit from the available local labour pool which is rich in healthcare and research talent. The Company is to employ additional staff onsite who will be needed to operate a 24/7 service. The laboratory will not only serve the local community but also support SourceBio's global partners across the United States. Jay LeCoque, Executive Chairman, commented: "SourceBio has already processed approaching 1,000,000 COVID-19 antigen RT-PCR tests in the UK for the DHSC and the NHS, Private Hospital Groups and Commercial customers since first offering its service in May 2020. "This further investment in our San Diego facility increases our overall capacity to increase COVID-19 qPCR testing services by up to an additional 5,000 samples per day and means we can address the clear market demand for COVID-19 testing in the US." Full release - hTTps://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-US-expansion-of-COVID/84481983
wan
02/3/2021
18:34
You better hope share prices does not touch 60 now wan as so far the market has refused to take your daily posts into account.I received so much stick early Nov last year when I said the share price was ahead of itself. I guess this is quite an emotional game for most. It shouldn't as this game is the hight of capitalism. Fiercely competitive. Cold blooded logic only works.
tongosti
Chat Pages: 127  126  125  124  123  122  121  120  119  118  117  116  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210308 00:28:40